Illustration of glucose and amino acid transport in brain cancer cells

Decoding Brain Cancer: How Glucose and Amino Acid Transporters Hold the Key

Author's portrait.
Nico Varela in Health & Wellness June 2025 • 5 min read.

"Unlocking new treatment avenues for primary central nervous system lymphoma (PCNSL) by understanding the roles of GLUT3 and LAT1."


Primary central nervous system lymphoma (PCNSL) is a particularly aggressive type of non-Hodgkin lymphoma, often presenting a challenging prognosis. While treatments have evolved, the fundamental mechanisms that drive the growth and metabolic demands of these cancer cells remain an area of intense investigation.

Positron emission tomography (PET) scans, utilizing tracers like [18F] 2-fluoro-2-deoxy-D-glucose (FDG) and L-(methyl-¹¹C)-methionine (MET), have become essential tools in visualizing and assessing PCNSL. These tracers highlight areas of high metabolic activity within the tumor, indicating increased glucose and amino acid uptake. However, precisely how these cancer cells manage to ramp up their intake of these critical nutrients has not been fully elucidated.

Recent research has focused on the roles of specific transporter proteins, namely glucose transporter (GLUT)1, GLUT3, and L-type amino acid transporter 1 (LAT1). These proteins are responsible for shuttling glucose and amino acids across the cell membrane, fueling the rapid growth and proliferation characteristic of cancer. A study published in Molecular and Clinical Oncology sought to determine if the expression levels of these transporters correlated with FDG and MET uptake in PCNSL tumors, potentially identifying new therapeutic targets.

GLUT3 and LAT1: The Gatekeepers of Tumor Metabolism?

Illustration of glucose and amino acid transport in brain cancer cells

The study involved analyzing resected PCNSL specimens from seven patients, meticulously measuring the mRNA expression levels of GLUT1, GLUT3, and LAT1. These levels were then correlated with the maximum standardized uptake values (SUVmax) obtained from FDG-PET and MET-PET scans, providing a direct link between transporter expression and tracer uptake. The research team also assessed microvessel density (MVD) and cell density (CD) in the tumor samples to evaluate the potential influence of vascularity and cellularity on tracer accumulation.

The results revealed a significant correlation between GLUT3 mRNA expression and FDG SUVmax, suggesting that GLUT3 plays a key role in glucose uptake in PCNSL cells. Similarly, a significant correlation was found between LAT1 mRNA expression and MET SUVmax, indicating that LAT1 is a crucial determinant of methionine uptake. Interestingly, neither MVD nor CD showed a significant association with FDG or MET uptake, highlighting the importance of these specific transporters in driving metabolic activity.

  • GLUT3 and FDG Uptake: Higher GLUT3 expression strongly correlated with increased FDG uptake, suggesting GLUT3 is crucial for glucose metabolism in PCNSL.
  • LAT1 and MET Uptake: Increased LAT1 expression significantly correlated with higher MET uptake, confirming LAT1's role in amino acid transport in these cancers.
  • MVD and CD: Microvessel density and cell density did not significantly affect FDG or MET uptake, shifting focus to the transporters themselves.
These findings suggest that PCNSL cells rely heavily on GLUT3 and LAT1 to fuel their metabolic demands. By upregulating these transporters, the cancer cells ensure a constant supply of glucose and essential amino acids, supporting their rapid growth and proliferation. This dependence on specific transporters opens up exciting possibilities for targeted therapies that could disrupt tumor metabolism and halt disease progression.

Future Directions: Targeting Transporters for PCNSL Treatment

The study's findings pave the way for the development of novel therapeutic strategies that specifically target GLUT3 and LAT1. By inhibiting the activity of these transporters, it may be possible to starve PCNSL cells of essential nutrients, ultimately leading to tumor regression and improved patient outcomes. Further research is needed to explore the potential of these transporters as drug targets and to develop effective inhibitors that can selectively disrupt their function. While current treatments involving high-dose MTX chemotherapy and radiation therapy have improved survival rates, the need for more targeted and effective therapies remains paramount. GLUT3 and LAT1 represent promising avenues for future research and drug development in the fight against this aggressive form of brain cancer.

Everything You Need To Know

1

What is primary central nervous system lymphoma (PCNSL), and why is it crucial to understand its metabolic mechanisms?

Primary central nervous system lymphoma (PCNSL) is an aggressive form of non-Hodgkin lymphoma that affects the brain and spinal cord. It poses significant treatment challenges, necessitating a deeper understanding of its metabolic processes to develop more effective therapies. Current treatments involve high-dose MTX chemotherapy and radiation therapy.

2

What are GLUT3 and LAT1, and what roles do they play in the context of primary central nervous system lymphoma (PCNSL)?

GLUT3 is a glucose transporter protein, and LAT1 is an L-type amino acid transporter 1. These transporters are crucial for moving glucose and amino acids across cell membranes to fuel cell growth. The study suggests that PCNSL cells heavily depend on GLUT3 for glucose uptake and LAT1 for amino acid transport, supporting their rapid proliferation. Targeting these transporters could disrupt tumor metabolism.

3

How are PET scans, FDG, and MET used in the context of primary central nervous system lymphoma (PCNSL), and what do they reveal about tumor metabolism?

PET scans use tracers like [18F] 2-fluoro-2-deoxy-D-glucose (FDG) and L-(methyl-¹¹C)-methionine (MET) to visualize metabolic activity in PCNSL tumors. FDG highlights glucose uptake, while MET indicates amino acid uptake. The maximum standardized uptake values (SUVmax) from these scans correlate with the expression levels of GLUT3 and LAT1, providing insights into how cancer cells manage nutrient intake. Microvessel density (MVD) and cell density (CD) did not significantly affect FDG or MET uptake.

4

What did the *Molecular and Clinical Oncology* study reveal about the relationship between GLUT3, LAT1, FDG uptake, and MET uptake in PCNSL tumors?

The study found a significant correlation between GLUT3 mRNA expression and FDG SUVmax, as well as between LAT1 mRNA expression and MET SUVmax in PCNSL tumors. Higher GLUT3 expression was associated with increased glucose uptake, and higher LAT1 expression correlated with increased methionine uptake. This indicates that GLUT3 and LAT1 play key roles in the metabolic demands of these cancer cells. Neither microvessel density (MVD) nor cell density (CD) showed a significant association with FDG or MET uptake.

5

What potential therapeutic strategies could arise from targeting GLUT3 and LAT1 in primary central nervous system lymphoma (PCNSL), and what future research is needed?

Targeting GLUT3 and LAT1 offers a promising therapeutic strategy for PCNSL. By inhibiting these transporters, it may be possible to disrupt the nutrient supply to cancer cells, leading to tumor regression. Further research is needed to develop effective inhibitors that selectively disrupt their function, potentially improving patient outcomes. This approach represents a shift towards more targeted therapies, addressing the need for more effective treatments beyond current options like high-dose MTX chemotherapy and radiation therapy.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.